Biotech Values

[DewDiligence]

You’re referring to the FDA’s Nov 2007 request for Lovenox immunogenicity data. Since ANDA’s do not have Complete Response Letters, the Nov 2007 FDA correspondence was pigeonholed as a “non-approvable” letter but it was tantamount to a delay rather than a rejection.